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Abstract
Background: Response gene to complement-32 (RGC-32) is comprehensively expressed in many kinds of tissues
and has been reported to be expressed abnormally in different kinds of human tumors. However, the role of RGC-
32 in cancer remains controversial and no reports have described the effect of RGC-32 in pancreatic cancer. The
present study investigated the expression of RGC-32 in pancreatic cancer tissues and explored the role of RGC-32
in transforming growth factor-beta (TGF-b)-induced epithelial-mesenchymal transition (EMT) in human pancreatic
cancer cell line BxPC-3.
Methods: Immunohistochemical staining of RGC-32 and E-cadherin was performed on specimens from 42 patients
with pancreatic cancer, 12 with chronic pancreatitis and 8 with normal pancreas. To evaluate the role of RGC-32 in
TGF-b-induced EMT in pancreatic cancer cells, BxPC-3 cells were treated with TGF-b1, and RGC-32 siRNA silencing
and gene overexpression were performed as well. The mRNA expression and protein expression of RGC-32 and
EMT markers such E-cadherin and vimentin were determined by quantitative reverse transcription-PCR (qRT-PCR)
and western blot respectively. Finally, migration ability of BxPC-3 cells treated with TGF-b and RGC-32 siRNA
transfection was examined by transwell cell migration assay.
Results: We found stronger expression of RGC-32 and higher abnormal expression rate of E-cadherin in pancreatic
cancer tissues than those in chronic pancreatitis tissues and normal pancreatic tissues. Immunohistochemical
analysis revealed that both RGC-32 positive expression and E-cadherin abnormal expression in pancreatic cancer
were correlated with lymph node metastasis and TNM staging. In addition, a significant and positive correlation
was found between positive expression of RGC-32 and abnormal expression of E-cadherin. Furthermore, in vitro,
we found sustained TGF-b stimuli induced EMT and up-regulated RGC-32 expression in BxPC-3 cells. By means of
siRNA silencing and gene overexpression, we further demonstrated that RGC-32 mediated TGF-b-induced EMT and
migration in BxPC-3 cells.
Conclusions: The results above indicated that RGC-32 might be a novel metastasis promoting gene in pancreatic
cancer and it enhances metastatic phenotype by mediating TGF-b-induced EMT in human pancreatic cancer cell
line BxPC-3.
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Pancreatic cancer is one of the most lethal human can-
cers due to its high metastatic potential, late manifesta-
tion of symptoms and strong chemoresistance [1].
Although more and more therapies including surgical
resection, chemotherapy and radiotherapy have been
used in recent years, patients’ overall 5-year survival rate
is still less than 5% [2]. Critical progress needs to be
made with regard to the metastasis mechanism of pan-
creatic cancer for early diagnosis and treatment of this
deadly disease.
Accumulating evidences have indicated that epithelial-
mesenchymal transition (EMT), which was originally
found in embryogenesis, contributes to tumor invasion,
metastatic dissemination and acquisition of therapeutic
resistance [3]. During the process of EMT, epithelial
cells change from their epithelial characteristics includ-
ing cell-cell adhesion, apical-basal polarity and lack of
motility to mesenchymal features, such as invasiveness,
motility and high resistance to cell death [3]. Besides, a
series of molecular events occur including down-regula-
tion of epithelial markers such as E-cadherin and up-
regulation of mesenchymal markers such as N-cadherin
and vimentin [4].
Transforming growth factor-beta (TGF-b) is a ubiqui-
tously multifunctional cytokine which controls lots of
biological events such as development, differentiation
and survival of essentially all cell types and tissues [5].
Recently, increasing attention has been paid to its role in
the regulation of tumor development and progression.
TGF-b is known to play a dual role in tumorigenesis.
TGF-b exerts antiproliferative effects in an early phase of
tumorigenesis while contributes to tumor progression
with aberrations in TGF-b signaling system in later stages
of tumorigenesis [5]. TGF-b overexpression has been
found in most pancreatic cancer and clinicopathological
analysis showed that TGF-b expression was significantly
correlated with lymph node metastasis and the depth of
invasion [5]. TGF-b and its downstream signaling mole-
cules have been shown to play a critical role in EMT of
pancreatic cancer [6-9]. However, the mechanism by
which TGF-b induces EMT has not been clear yet.
Response gene to complement (RGC)-32 was first
cloned by Badea et al. in 1998 and was comprehensively
expressed in many kinds of tissues such as placenta, kid-
ney, pancreas, liver, heart, brain, etc. [10,11]. It has been
reported that RGC-32 plays an important role in cell
proliferation and differentiation [11,12]. However, the
role of RGC-32 in cancer remains controversial. RGC-
32 expression has been found to be up-regulated in
tumors such as colon, breast and prostate cancer but
down-regulated in advanced stages of primary astrocyto-
mas [13,14]. Similarly, studies on RGC-32 mRNA
expression in various metastatic cancers have also
yielded different results [15,16].These studies suggested
that RGC-32 plays a complex role in cancer and the
effect of RGC-32 may vary among cancers of different
organs or tissues. Until now, to our knowledge, no
reports have described the role of RGC-32 in pancreatic
cancer. In the present study, we found for the first time
that the expression of RGC-32 was up-regulated in pan-
creatic cancer and was correlated with lymph node
metastasis and TNM staging. In addition, a significant
and positive correlation was found between positive
expression of RGC-32 and abnormal expression of E-
cadherin. Furthermore, we demonstrated that RGC-32,
as a downstream target of TGF-b, played an important
role in inducing EMT as well as promoting cell migra-
tion in human pancreatic cancer cell line BxPC-3. The
results above implicated that RGC-32 might serve as a
novel metastasis promoting factor and promote tumor
metastasis by mediating TGF-b-induced EMT.
Materials and methods
Tissue samples
The study was approved by the Ethics Committee of
Tongji Hospital of Tongji medical college, and informed
consent was obtained from each patient. Tumor samples
were obtained from 42 patients with pancreatic cancer
who had underwent surgery at Tongji Hospital of Tongji
Medical College, Wuhan, China during 2005 and 2010.
Another 12 chronic pancreatitis tissues and 8 normal
pancreatic tissues serving for control were obtained
from the same hospital. None of these patients received
preoperative treatment, such as chemotherapy or radio-
therapy. All of the tumors were confirmed to be pan-
creatic cancer by clinicopathological examinations. All
the cases were classified according to the latest AJCC
cancer staging manual [17].
Immunohistochemistry
All the resected specimens were fixed in 10% buffered
formalin and embedded in paraffin. Sections were pre-
pared, and deparaffinized through graded alcohol and
xylene, and then washed three times with cold 0.01
mol/L phosphate-buffered saline (PBS). Afterwards,
endogenous peroxidase was blocked with 3% hydrogen
peroxide in methanol for 20 min. The sections were
washed again in PBS three times. Antigen retrieval was
accomplished by boiling the slides in the autoclave for
10 min in 10 mmol/L sodium citrate. After treatment
with 10% bovine serum, the sections were incubated
overnight at 4°C with rabbit polyclonal antibody against
RGC-32 (Santa Cruz Biotechnology, USA, diluted 1:50)
and E-cadherin (ProteinTech Group, Inc., USA, diluted
1:100), followed by incubation with biotinylated goat
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reagent (SP kit, ZhongShan goldenbridge biotechnology
CO. LTD, China). For the negative control, the immu-
nostaining processes were performed by replacing the
primary antibody with PBS. Finally, the reaction was
visualized with a chromogen, diaminobenzidine in 3%
hydrogen peroxidase. Sections were then counterstained
with hematoxylin, dehydrated and mounted. Slides were
evaluated by two independent pathologists who were
blinded to the clinicopathological details.
The intensity of RGC-32 staining was graded as pre-
viously described [18]: negative (-), slight positive (+),
positive (++), and highly positive (+++). The expression
of E-cadherin was judged as two categories, normal and
abnormal according to the method previously described
[19]: the staining pattern was classified into four groups.
Only a membranous pattern, which stained as strongly
as normal epithelial cells, was judged as normal. In con-
trast, absent pattern (loss of staining), cytoplasmic pat-
tern (cytoplasmic staining with loss of membranous
expression) and heterogeneous pattern (cytoplasmic
staining with preservation of membranous expression)
were considered abnormal.
Cell culture and morphologic analysis
Human pancreatic cancer cell line BxPC-3 was pur-
chased from American Type Culture Collection (ATCC)
and cultured in RPMI-1640 medium containing 10%
fetal bovine serum (FBS) at 37°C in a 95% O2 and 5%
CO2 incubator. BxPC-3 cells were grown to about 60%
confluency in RPMI-1640+ 10% FBS and were then
serum-deprived overnight in RPMI-1640 medium. Cells
were then treated with 10 ng/ml TGF-b1( P e p r o t e c h
Inc., USA.) for 72 h. The morphology of cells was visua-
lized with a phase contrast microscope (×200, Nikon,
Japan) and imaged with digital photography.
Construction of RGC-32 expression plasmid and RGC-32
short interfering RNA (siRNA)
RGC-32 cDNA was amplified from mRNA extracted
from BxPC-3 cells and then cloned into pcDNA3.1/myc-
His C expression vector(Invitrogen, USA)between Hind
III and BamH I restriction sites. The cloned cDNA was
verified by sequencing. siRNA targeting human RGC-32
(5’ CAGAUUCACUUUAUAGGAA 3’ and 5’ UUC-
CUAUAAAGUGAAUCUG 3’ duplex) was synthesized
by Ribobio Co. (Guang Zhou, China). A scrambled
duplex siRNA was used as the negative control.
Transient transfection of RGC-32 expression plasmid
BxPC-3 cells were plated at 3 × 10
5/well in 6-well plates
and incubated until they reached 95% confluency. Cells
were then transiently transfected with lipofectamine
2000 (Invitrogen, USA) according to the manufacturer’s
recommendations. 4.0 μgo fp l a s m i dD N Aa n d1 0μlo f
lipofectamine 2000 were diluted separately in Opti-
MEM I medium (Gibco, USA) and incubated for 5 min.
They were then combined and incubated for 30 min at
room temperature. The complexes were added to each
well and mixed gently, followed by incubation at 37°C. 5
h later, the medium was replaced with RPMI-1640 med-
ium containing 10% fetal bovine serum. Cells were then
incubated for 48 h and 72 h respectively for RNA isola-
tion and protein exaction.
siRNA transfection
BxPC-3 cells were plated at 1 × 10
5/well in 6-well plates
and incubated until they reached 50% confluency. Cells
were transfected with RGC-32 siRNA or the negative
control siRNA at a final concentration of 50 nM with
lipofectamine 2000 according to the manufacturer’s
instructions. 6 h after initiation of transfection, cells
were starved in serum-free RPMI-1640 for another 6 h,
followed by treatment with or without 10 ng/ml TGF-
b1 for 72 h.
RNA isolation and quantitative reverse transcription-PCR
(qRT-PCR)
Total RNA was isolated from BxPC-3 cells by TRIzol
reagent (Invitrogen, USA) according to the manufac-
turer’s instructions and was resuspended in nuclease-
free water. 2 μg of total RNA was added to 25 μlo f
reverse transcription reaction mixture containing 5 μlo f
5 × RT Reaction Buffer, 3 μl of dNTPs (10 mmol/L), 1
μl of Oligo (dT), 1 μl of M-MLV (Promega, USA), 1 μl
of Rnasin (Fermentas, USA) and indicated amount of
DEPC water. The reverse transcription reaction was pro-
cessed at 70°C for 5 min, 37°C for 1 h and 85°C for 10
min. qPCR was performed with StepOne Real-time PCR
systems (ABI, USA) in a reaction volume of 20 μlc o n -
taining 2 μl of cDNA, 0.8 μl of forward primer (10 nM),
0.8 μl of reverse primer (10 nM), 10 μl of SYBR Green
Realtime PCR Master Mix (Toyobo, Japan) and 6.4 μlo f
ddH2O. The qPCR was processed at 95°C for 60 s, fol-
lowed by 40 cycles of 95°C for 15 s and 60°C for 30 s
(data collection). All the qPCR reactions were performed
in triplicate. The analysis of qPCR was carried out using
the 2
-ΔΔCt method. b-actin was taken as the internal
control. The nucleotide sequences of the primers were
listed in Table 1. All the primers were synthesized by
Shanghai Sangon Biological Engineering & Technology
and Service Co. Ltd, China.
Western blot
Total protein extraction from BxPC-3 cells and western
blot analysis was performed following the protocol as
described previously [20]. Briefly, 80 μg of cell protein
was eletrophoresed on a 12% SDS/polyacrylamide gel in
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branes. The nitrocellulose membranes were then
blocked at room temperature for 2 h in blocking buffer
(5% skim milk in TBST) and incubated with RGC-32
antibody (diluted 1:200), E-cadherin antibody (diluted
1:400) and vimentin antibody (ProteinTech Group, Inc.,
USA, diluted 1:1000) respectively overnight at 4°C with
b-actin antibody (ProteinTech Group, Inc., USA, diluted
1:1000) as control. Washed thrice with TBST, nitrocellu-
lose membranes were incubated in HRP-conjugated goat
anti-rabbit secondary antibody (Boster, China, diluted
1:3000) for 1 h at room temperature. Extensive washed
with TBST, the complex was detected by Super Signal
West Pico Chemiluminescent Substrate (Thermo Fisher
Scientific Inc, USA) according to the manufacturer’s
instructions. Blot was scanned and densitometric analy-
sis was done by Image J software (National Institutes of
Health, USA).
Transwell cell migration assay
BxPC-3 cells were transfected with RGC-32 siRNA or
the negative control siRNA and treated with 10 ng/ml
TGF-b1 or not as described above. 24 h later, the cells
were trypsinized, adjusted to 1 × 10
6/ml in RPMI-1640
medium, and 200 μl of the resuspended cell solution
w a sa d d e dt ot h et o pc h a m b e ro f2 4 - w e l lt r a n s w e l l
plates. The bottom chamber was filled with 600 μlo f
RPMI-1640 medium containing 10% FBS. The transwell
plate was assembled and incubated at 37°C in a 5% CO2
incubator. 24 h later, the top chamber was removed,
washed with PBS, and fixed with 40 ml/l paraformalde-
hyde for 20 min. Unmigrated cells staying at the upper
layer of the microporous membrane were gently scraped
with a wet cotton swab and the migrated cells at the
lower layer were stained by 0.1% of crystal violet for 10
min. The top chamber was then washed with PBS to
remove excess stain and dried. The stained migrated
cells were visualized with the phase contrast microscope.
The average number of migrated cells per field was
quantified under high power (×200).
Statistical analysis
Data were presented as mean ± standard deviation (SD).
Experiments were repeated at least three times. SPSS
17.0 software (IBM, USA) was used for data analysis.
Group differences were analyzed by Student t test, ana-
lysis of variance (ANOVA), c
2 test or Fisher exact test
according to the data type. Spearman rank correlation
analysis was used to examine the correlation between
RGC-32 positive expression and E-cadherin abnormal
expression in pancreatic cancer tissues. P < 0.05 was
considered statistically significant.
Results
The expression of RGC-32 and E-cadherin in normal
pancreas, chronic pancreatitis and pancreatic cancer
tissues and the relationships with clinicopathological
features
Immunohistochemical staining revealed that RGC-32
was expressed in pancreatic cancer as well as chronic
pancreatitis and normal pancreas. RGC-32 staining was
predominantly observed in the cytoplasm of pancreatic
acinar cells (Figure 1A-C). Both the positive expression
rate and staining intensity of RGC-32 in pancreatic can-
cer tissues were significantly higher than those in nor-
mal pancreatic tissues and pancreatitis tissues, but no
significant differences were found between normal pan-
creatic tissues and pancreatitis tissues (Table 2).
The positive staining for E-cadherin was mainly
observed in the cytomembrane of normal pancreatic aci-
nar cells (normal expression), but might be found in the
cytoplasm and/or become weaker in pancreatic cancer
cells (abnormal expression) (Figure 1D-F). The abnor-
mal expression rate of E-cadherin was significantly
increased in pancreatic cancer tissues compared with
normal pancreas and chronic pancreatitis tissues, but no
significant differences were found between normal pan-
creatic tissues and pancreatitis tissues (Table 2).
The relationships between immunostaining and clini-
copathological characteristics of all 42 pancreatic cancer
patients were shown in Table 3. Age and gender showed
Table 1 PCR primers used in the experiments
Target mRNA Primer sequences 5’-3’ Product Size
(bp)
Gene Bank Accession No
RGC-32 sense TGCCAGAGGGGACAAAGAC 127 NM_014059.2
RGC-32 antisense GCAAGCAGGTAAACAAAGTCAG
E-cadherin sense ACAGCCCCGCCTTATGATTCTC 140 NM_004360.3
E-cadherin antisense AAGCGATTGCCCCATTCGTT
vimentin sense CCTTGAACGCAAAGTGGAATC 106 NM_003380.3
vimenin antisense GACATGCTGTTCCTGAATCTGAG
b-actin sense GTTGCGTTACACCCTTTCTTG 157 NM_001101.3
b-actin antisense GACTGCTGTCACCTTCACCGT
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0.05). Both lymph node metastasis and TNM staging
were significantly correlated with RGC-32 and E-cad-
herin (P < 0.05). The positive expression rate of RGC-32
and the abnormal expression rate of E-cadherin were
found to be increased in tumors with a less advanced
pathological stage and higher TNM classification.
Tumor differentiation was also correlated with abnormal
expression rate of E-cadherin (P < 0.05) but not with
the expression of RGC-32 (P > 0.05). The abnormal E-
cadherin expression rate was higher in poorly-differen-
tiated-type tumors than in well-differentiated-type
counterparts.
Furthermore, a significant and positive correlation was
found between positive expression of RGC-32 and
abnormal expression of E-cadherin (R = 0.458, P < 0.01,
Table 4).
TGF-b induces EMT and enhances RGC-32
expression in BxPC-3 cells
TGF-b1 (10 ng/ml) treatment of pancreatic cancer cell
line BxPC-3 for 72 h caused remarkable changes in cell
morphology from a more epithelial-like appearance to a
mesenchymal-like spindle-cell shape and increased inter-
cellular separation (Figure 2A). Furthermore, qRT-PCR
showed that E-cadherin mRNA expression was gradually
decreased with significant down-regulation at 48 h of
TGF-b1 treatment and remained descending until 72 h,
the longest time tested, while vimentin mRNA expression
was up-regulated significantly as early as 24 h of TGF-b1
Figure 1 Representative immunohistochemical staining for RGC-32(A-C) and E-cadherin (D-F) in pancreatic cancer, chronic pancreatitis
and normal pancreas tissues (original magnification × 200). (A) RGC-32 highly positive staining in pancreatic cancer tissues (B) RGC-32
positive staining in chronic pancreatitis tissues (C) RGC-32 slightly positive staining in normal pancreas tissues (D) normal membranous E-
cadherin staining (membranous pattern) in pancreatic cancer tissues (E) cytoplasmic staining with loss of membranous expression (cytoplasmic
pattern) in pancreatic cancer tissues (F) loss of E-cadherin staining (absent pattern) in pancreatic cancer tissues.
Table 2 Expression of RGC-32 and E-cadherin in normal pancreas, chronic pancreatitis and pancreatic cancer tissues
Tissue RGC-32 staining intensity E-cadherin
- + ++ +++ Positive/total P-value normal abnormal P-value
Normal pancreas 5 3 0 0 3/8 1.000
a 8 0 1.000
a
Chronic pancreatitis 7 3 2 0 5/12 0.028
b 11 1 0.004
b
Pancreatic cancer 9 5 12 16 33/42 0.030
c 19 23 0.005
c
a, normal pancreas compared with chronic pancreatitis
b, chronic pancreatitis compared with pancreatic cancer
c, pancreatic cancer compared with normal pancreas
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Western blot detecting E-cadherin and vimentin protein
expression showed similar results (Figure 2C and 2D).
Taken together, we confirmed that sustained TGF-b1 sti-
muli induced EMT in BxPC-3 cells, which was consistent
with the report by Vogelmann R et al [9]. In addition,
qRT-PCR demonstrated that RGC-32 mRNA expression
was up-regulated significantly at 48 h of TGF-b1t r e a t -
ment and dramatically increased by about 6 folds at 72 h
of treatment (Figure 2B) and western blot showed that
RGC-32 protein expression was up-regulated significantly
within 48 h of treatment (Figure 2C). These results above
indicated that TGF-b enhanced RGC-32 expression as
well as inducing EMT in BxPC-3 cells.
RGC-32 overexpression induces EMT
independently in BxPC-3 cells
To investigate whether RGC-32 alone could induce EMT
in BxPC-3 cells, we transiently transfected RGC-32 plas-
mid (pcDNA3.1/myc-His C-RGC-32) into BxPC-3 cells to
overexpress RGC-32. Empty vector (pcDNA3.1/myc-His
C) was used as a negative control. mRNA expression and
Table 3 Correlation between clinicopathological findings
and immunochemical staining
cases RGC-32 positive Abnormal
E-cadherin
n % P-value n % P-value
Age 0.831 0.990
< 45 7 5 71.4 4 57.1
45-59 22 18 81.8 12 54.5
> = 60 13 10 76.9 7 53.8
Gender 1.000 1.000
Male 21 17 81.0 11 52.4
Female 21 16 76.2 12 57.1
Differentiation 0.629 0.024
Well 16 12 75.0 5 31.3
Moderately 11 8 72.7 6 54.5
Poorly 15 13 86.7 12 80.0
Lymph node metastasis 0.016 0.004
Negative 16 9 56.3 4 25.0
Positive 26 24 92.3 19 73.1
TNM staging 0.025 0.004
I-II 18 11 61.1 5 27.8
III-IV 24 22 91.7 18 75.0
Table 4 Correlation between RGC-32 expression and E-
cadherin expression in pancreatic cancer tissues
E-cadherin
abnormal normal R-value P-value
RGC-32 + 22 11 0.458 0.002
-1 8
Figure 2 TGF-b induces EMT and enhances RGC-32 expression
in BxPC-3 cells. BxPC-3 cells were cultured and treated with 10 ng/
ml of TGF-b1 for 24 h, 48 h and 72 h, respectively. The morphology
of cells at 72 h of TGF-b1 treatment was visualized with a phase
contrast microscope (original magnification × 200, Nikon). (A) mRNA
expression of E-cadherin, vimentin and RGC-32 was quantified by
qRT-PCR with b-actin as an internal control. (B) Protein expression of
E-cadherin, vimentin and RGC-32 was detected by western blot, (C)
and normalized by b-actin (D). *P < 0.05 compared with the control
group (0 h).
Figure 3 RGC-32 overexpression promotes EMT of BxPC-3 cells.
BxPC-3 cells were transiently transfected with RGC-32 plasmid
(pcDNA3.1/myc-His C-RGC32) or empty vector (pcDNA3.1/myc-His
C). 72 h after transfection, qPCR (A) and western blot (B and C)
were performed to examine the expression of RGC-32, E-cadherin
and vimentin at mRNA and protein levels respectively. b-actin was
used as an internal control. *P < 0.05.
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and vimentin were detected by qRT-PCR and western blot
respectively. As shown in Figure 3, RGC-32 overexpres-
sion significantly down-regulated E-cadherin expression
and up-regulated vimentin expression at both mRNA and
protein levels, indicating that RGC-32 overexpression
induced EMT in BxPC-3 cells independently.
RGC-32 mediates TGF-b-induced EMT in BxPC-3
cells
We used RNA interference technique to further deter-
m i n et h er o l eo fR G C - 3 2i nT G F - b-induced EMT. As
shown in Figure 4, compared with the negative control,
RGC-32 siRNA transfection significantly attenuated the
expression of RGC-32 mRNA and in turn led to the
inhibition of RGC-32 proteine x p r e s s i o n .M e a n w h i l e ,
TGF-b-induced up-regulation of vimentin and down-
regulation of E-cadherin was remarkably blocked by
RGC-32 silencing, indicating that RGC-32 played a criti-
cal role in TGF-b-induced EMT.
RGC-32 mediates TGF-b-induced migration of
BxPC-3 cells
We used transwell cell migration assay to examine the
role of RGC-32 in cell migration of BxPC-3 cells. As
s h o w ni nF i g u r e5 ,T G F - b treatment promoted the
migration of BxPC-3 cells while RGC-32 RNA silencing
remarkably blocked this effect, implicating that RGC-32
mediated TGF-b-induced migration of BxPC-3 cells.
Discussion
Recent studies have implicated EMT in cancer progres-
sion by showing that epithelial-like tumor cells could
switch to a mesenchymal-like phenotype that facilitates
motility and invasion [21]. EMT-related molecular path-
ways have been extensively investigated, and various
genes and molecules have been identified as important
factors in EMT, of which TGF-b has been most studied
and believed to be the major inducer in pancreatic cancer
[22]. It has been demonstrated that when TGF-b binds to
the TGFbRII, TGFbRI becomes phosphorylated and pro-
pagates the signal downstream through phosphorylation
and thereby activation of the Smad2 and Smad3 proteins
(receptor Smads). The activated receptor Smads form a
complex with Smad4 and translocate into the nucleus to
regulate the expression of genes involved in EMT [23,24].
Beside Smad-mediated transduction, TGF-b also induces
EMT via Smad-independent signaling cascades including
PI3K, MAPK, Rho kinase pathways and so on [25]. Our
research demonstrated that constant stimuli by TGF-b
induced EMT in BxPC-3 cells and the observed changes
were proposed to be independent of Smad pathway
because Smad4 is homozygous deleted in BxPC-3 cells
[26]. The result was consistent with that in Vogelmann R
et al’s research [9]. However, the downstream effectors of
Smad-independent pathways mediating TGF-b-induced
EMT remain largely unknown. In particular, it has been
reported that mutation or deletion of Smad4 is found in
about 50% of pancreatic tumors and is correlated with
poor prognosis [27]. Thus, it may be more important to
investigate Smad-independent pathways in detail in order
to further understand invasion and metastasis of pancrea-
tic cancer.
Recently several studies have shown that RGC-32
plays an important role in EMT. Fengmin Li et al [12]
reported that RGC-32, regulated by both Smad and
RhoA, participated in TGF-b-induced smooth muscle
differentiation from neural crest cells and Wen-Yan
H u a n ge ta l[ 2 8 ]s h o w e dt h a tR G C - 3 2 ,a c t i n gd o w n -
stream of Smad, mediated TGF-b-induced EMT of
human proximal tubular cells (HPTCs). However, as far
as we know, there have been no reports about the role
of RGC-32 in pancreatic cancer. In this study, by means
of immunohistochemical staining, we found for the first
time that the expression of RGC-32 was up-regulated in
pancreatic cancer and was correlated with lymph node
metastasis and TNM staging, which suggested that
RGC-32 might be a novel tumor metastasis promoting
factor for pancreatic cancer.
Figure 4 RGC-32 mediates TGF-b-induced EMT in BxPC-3 cells.
BxPC-3 cells were transfected with RGC-32 siRNA (siRGC-32) or
negative control siRNA (siCtrl). 6 h later, cells were starved in serum-
free RPMI-1640 for additional 6 h, followed by treatment with or
without 10 ng/ml TGF-b1 for 72 h. The mRNA expression and
protein expression of RGC-32, E-cadherin and vimentin were
examined by qRT-PCR (A) and western blot (B and C) respectively.
b-actin was used as an internal control. RGC-32 silencing
significantly blocked TGF-b-induced EMT in BxPC-3 cells. *P < 0.05.
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cess of EMT, which has been implicated in cell-cell adhe-
sion and maintenance of normal tissue architecture [29].
E-cadherin interacts at a conserved cytoplasmic domain
with the cytoskeleton via associated cytoplasmic mole-
cules, a-, b- and g-catenin [29]. It has been demonstrated
by many researches that abnormalities in expression and
function of the adhesion complex have been found in pan-
creatic cancer and were believed to result in loss of cell-
cell adhesion and contribute to the invasiness and metas-
tasis of tumor [30,31]. Immunohistochemical analysis in
our research showed that abnormal E-cadherin expression
rate was higher in pancreatic cancer tissues than that in
chronic pancreatitis and normal pancreatic tissues, and
was correlated with clinicopathological features such as
tumor differentiation, lymph node metastasis and TNM
staging. The results were consistent with those in a
research of early gastric cancer [32]. Furthermore, we
found for the first time that there was a significant and
positive correlation between positive expression of RGC-
32 and abnormal expression of E-cadherin, which impli-
cating that RGC-32 might promote metastasis by control-
ling EMT of pancreatic cancer.
In order to clarify whether RGC-32 is involved in EMT
and to investigate its upstream regulator in pancreatic can-
cer, we focused on its role in TGF-b signaling pathway in
vitro. TGF-b-induced-EMT model in BxPC-3 cells showed
increased expression of RGC-32 at both mRNA and pro-
tein levels, indicating that RGC-32 might be involved in
TGF-b-induced EMT. In addition, RGC-32 RNA silencing
blocked EMT induced by TGF-b in BxPC-3 cells, confirm-
ing that RGC-32 mediates TGF-b-induced EMT. Further-
more, overexpression of RGC-32 demonstrated that RGC-
32 can induce EMT independently in BxPC-3 cells. Spe-
cially, given that Smad4 is homozygous deleted in BxPC-3
cells, we suppose that RGC-32 induces EMT independent
of Smad pathway and that RGC-32 may be a critical effec-
tor in Smad-independent pathways. It is important to note
that our results were not the same as those in neural crest
cells and HPTCs in which RGC-32 is a downstream target
of Smad pathways, indicating that the activation pathway
and effect of RGC-32 between normal development and
carcinogenesis may be controlled by different mechanisms.
Finally, by means of transwell cell migration assay we
f u r t h e rs h o w e dt h a tR G C - 3 2m e d i a t e dT G F - b-induced
cell migration in BxPC-3 cells, implicating that RGC-32
helps to enhance metastatic phenotype in vitro.
Conclusions
To sum up, an important issue addressed in this study is
that RGC-32 might be a novel metastasis promoting fac-
tor for pancreatic cancer and it enhances metastatic
phenotype by mediating TGF-b-induced EMT indepen-
dent of Smad pathway in pancreatic cancer cell line
BxPC-3. These findings described for the first time the
role of RGC-32 in the progression of pancreatic cancer
and indicated that RGC-32 might be a new target for
inhibiting metastatic dissemination of pancreatic cancer.
Further exploration of the concrete mechanism by
which RGC-32 induces EMT is needed to fully under-
stand its role in the process of EMT and metastasis of
pancreatic cancer.
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